

Anthony P. Nicholas
Sanjoy K. Bhattacharya
Paul R. Thompson *Editors*

Protein Deimination in Human Health and Disease

Second Edition

 Springer

Protein Deimination in Human Health and Disease

Anthony P. Nicholas • Sanjoy K. Bhattacharya
Paul R. Thompson
Editors

Protein Deimination in Human Health and Disease

Second Edition

 Springer

Editors

Anthony P. Nicholas
Department of Neurology
University of Alabama at Birmingham
and The Birmingham Veterans
Administration Medical Center
Birmingham, AL, USA

Sanjoy K. Bhattacharya
Bascom Palmer Eye Institute
University of Miami
Miami, FL, USA

Paul R. Thompson
Department of Biochemistry and Molecular
Pharmacology
UMASS Medical School
Worcester, MA, USA

ISBN 978-3-319-58243-6 ISBN 978-3-319-58244-3 (eBook)
DOI 10.1007/978-3-319-58244-3

Library of Congress Control Number: 2017948284

© Springer International Publishing AG 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by Springer Nature
The registered company is Springer International Publishing AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland



On behalf of the editors, I wish to dedicate this book to the memory of Kerri Anne Mowen, who sadly passed away at age 41 on February 14, 2016 of a brain aneurysm. Although I had long been familiar with her work, I first met Kerri in 2008 at the FASEB Methylation meeting where we shared our equal passion for both the protein arginine deiminases and protein arginine methyltransferases. What impressed me most about our first meeting was that Kerri was not only whip smart but also a joy to be around. We quickly became collaborators,

and most importantly friends, leading us eventually to cofound Padlock Therapeutics. Kerri's contributions to the PAD field are indelible and include developing both PAD2 and PAD4 knockout mice, helping establish the key role of PAD4 in NETosis, and establishing the importance of PAD4 activity in the initiation versus effector phases of rheumatoid arthritis. Her imprint on the PAD field will long be felt, and her future contributions sadly missed.

PRT

Contents

1 A History of Deimination Research in Japan: The Founding Fathers	1
Hidenari Takahara	
2 Aspects of Peptidylarginine Deiminase Regulation that May Predispose to Autoreactivity Against Citrullinated Proteins	11
Indira Neeli and Marko Radic	
3 Structures and Functions of Peptidylarginine Deiminases	33
Masaki Unno, Kenji Kizawa, and Hidenari Takahara	
4 The Use of Genetically Engineered Mice to Study PAD Biology and Pathology	47
Chinatsu Mukai, Brooke A. Marks, and Scott A. Coonrod	
5 PAD Activation in Arthritis	63
Dres Damgaard and Ger J.M. Pruijn	
6 Rheumatoid Arthritis: Transition from Systemic Autoimmunity to Joint Inflammation and Bone Loss	85
Bence Rethi, Akilan Krishnamurthy, and Anca I. Catrina	
7 <i>Porphyromonas gingivalis</i> Peptidyl Arginine Deiminase: A Unique Bacterial PAD with Implications for Periodontal Disease and Rheumatoid Arthritis	99
Katarzyna Gawron, Anna Montgomery, Katarzyna Łazarz-Bartyzel, Grzegorz Bereta, Maria Chomyszyn-Gajewska, Patrick Venables, and Jan Potempa	
8 Citrullination and Neutrophil Extracellular Traps	137
Nishant Dwivedi, Hui-Hsin Chang, and I-Cheng Ho	

9	Citrullination and Autophagy	161
	Guido Valesini, Tania Colasanti, Cristiano Alessandri, Michele Bombardieri, Fabrizio Conti, and Maurizio Sorice	
10	Antigen Deimination in Human Type 1 Diabetes and Nonobese Diabetic Mice	173
	Hai Nguyen and Eddie A. James	
11	Citrullinated Autoantigen Targets as Markers of Extra-Articular Disease in Rheumatoid Arthritis	191
	Vinitha Ganesan and Dana P. Ascherman	
12	The Significance of Myofilament Protein Citrullination in Heart Failure: Citrullination in Cardiovascular Diseases	205
	J. Fert-Bober, E.L. Crowgey, J. Sokolove, J.T. Giles, J.M. Bathon, and J.E. Van Eyk	
13	Protein Deimination in Protein Misfolding Disorders: Modeled in Human Induced Pluripotent Stem Cells (iPSCs)	227
	Sigrun Lange, Selina Wray, Mike Devine, Mar Matarin, and John Hardy	
14	Protein Deimination in Aging and Age-Related Diseases with Ocular Manifestations	241
	Di Ding, Mabel Enriquez-Algeciras, Sanjoy K. Bhattacharya, and Vera L. Bonilha	
15	Chemical Modification and Mass Spectrometric Approaches for Detection of Brain Protein Deimination	253
	Mabel Enriquez-Algeciras, Di Ding, Dana P. Ascherman, and Sanjoy K. Bhattacharya	
16	Citrullination Following Traumatic Brain Injury: A Mechanism for Ongoing Pathology Through Protein Modification	275
	Rachel C. Lazarus, John E. Buonora, Alaa Kamnaksh, Michael N. Flora, James G. Freedy, Gay R. Holstein, Giorgio P. Martinelli, David M. Jacobowitz, Denes Agoston, and Gregory P. Mueller	
17	Update on Deimination in Alzheimer's Disease	293
	Yoshitaka Kondo, Eun-Kyoung Choi, Yong-Sun Kim, and Akihito Ishigami	
18	Deimination in Multiple Sclerosis: The Bad, the Good, and the Ugly	317
	William R. Meador, John R. Rinker, and Anthony P. Nicholas	

19 Turning White Matter “Inside-Out” by Hyper-deimination of Myelin Basic Protein (MBP) 337
George Harauz

20 The Significance of Deiminated GFAP in Neurodegenerative Diseases with Special Emphasis on Alexander Disease 391
Michael Brenner and Anthony P. Nicholas

21 Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology 413
Sigrun Lange, Sharad Kholia, Uchini S. Kosgodage, and Jameel M. Inal

22 Citrullination in Inflammatory-Driven Carcinogenesis of the Colon 427
Erin E. Witalison and Lorne J. Hofseth

23 Development of the Protein Arginine Deiminase (PAD) Inhibitors 445
Aaron Muth and Paul R. Thompson

Index 467

Chapter 1

A History of Deimination Research in Japan: The Founding Fathers

Hidenari Takahara

The research on protein deimination and the enzymes responsible for catalyzing this posttranslational modification started from investigations of the hair follicle and myelin in central nerve system. About 60 years ago, in 1958, the presence of protein-bound citrulline was first reported by Dr. George Rogers (Adelaide University, Australia) in the protein of the inner root sheath (IRS) of hair follicles (Rogers 1958). In order to obtain information about the protein composition of the IRS, he conducted a quantitative amino acid analysis of an acid hydrolysate on sufficient amounts of IRS that were dissected from the vibrissae follicle of rats. At that time, the common method for separating amino acids was paper chromatography, and when applied to the IRS hydrolysates, citrulline was discovered as a distinct ninhydrin-positive spot in an area adjacent to the basic amino acids. About 10 years after Rogers's discovery, Dr. Mario Moscarello (Toronto University, Canada) started an intensive investigation of myelin sheath proteins in the central nerve system. In 1971, he also found the presence of peptide-bound citrulline in myelin basic protein (MBP) using similar methods to Rogers (Finch et al. 1971). Moscarello continued the investigation of MBP until he passed away in 2013, publishing many papers concerning the hyper-deimination of MBP in the pathology of multiple sclerosis. His research career involving the deimination of MBP was described in a eulogy in the first volume of this book series (Nicholas and Bhattacharya 2014).

Although it was unclear as to how the citrulline was incorporated into proteins, the source was thought to be arginine. In 1977, Rogers and colleagues (1977) were the first to conclusively demonstrate that arginine residues were indeed converted to citrulline via a deimination reaction where they combined hair follicle extracts with calcium to promote this reaction. Following this report, research to identify the specific deiminating enzyme was energetically carried out in Japan. In 1979, Dr. Kiyoshi Sugawara (Fig. 1.1; Ibaraki University, Japan) reported the presence of protein-bound

H. Takahara (✉)
College of Agriculture, Ibaraki University,
3-21-1, Chuuo, Ami, Inashiki 300-0393, Ibaraki, Japan
e-mail: hidenari86ta@msn.com

Fig. 1.1 The founding fathers: *left*, Professor Dr. George Rogers (Adelaide University, Australia). *Center*, Professor Dr. Hidenari Takahara (Ibaraki University, Japan). *Right*, Professor Dr. Kiyoshi Sugawara (Ibaraki University, Japan). Taken at the first International Symposium of Deimination and Skin Biology, April 2009 in Osaka, Japan



citrulline in the epidermal proteins of newborn rat (Sugawara 1979). Successively, he demonstrated the existence of the enzyme that converts arginyl to citrulline residues in the extracts from the newborn rat epidermis (Fujisaki and Sugawara 1981). To assay the enzyme activity, he introduced a colorimetric method using simple synthetic substrates of arginine blocked at the N- and C-terminals as a substrate. In this procedure, high temperatures (over 50 °C) and the presence of dithiothreitol (DTT) greatly enhanced enzyme activity. According to these procedures, he could overcome tedious and laborious work that was needed to measure enzyme activity using an amino acid analyzer. Dr. Sugawara then introduced the logical name peptidylarginine deiminase (PAD) for the enzyme, because it acts on arginine residues embedded in a peptide backbone and is distinct from deiminases that act on free arginine (Fujisaki and Sugawara 1981). In this year, PAD was registered as new enzyme to IUPAC Enzyme Committee and was classified into EC 3.5.3.15.

In 1982, I joined Dr. Sugawara's laboratory. This was just after he obtained a new finding that the extract from rabbit skeletal muscle contains very high deiminase activity, about 120-fold compared to that of the newborn rat epidermis. Since the available amounts of the newborn rat epidermis were very low and the tissue preparations were burdensome, the high abundance of a PAD in rabbit skeletal muscle was an exciting research finding that gave me a tremendous head start to further characterize this enzyme. My first research project at Ibaraki University was to purify the PAD from rabbit skeletal muscle. Very fortunately, I quickly purified the enzyme to homogeneity and determined the chemical, physiochemical, and kinetic properties toward several synthetic arginine derivatives including natural proteins (Takahara et al. 1983). This was the first and most definitive report demonstrating that the

enzyme could catalyze the conversion of arginyl to citulline residues in native protein substrates *in vitro*. Among the protein substrates examined using this purified PAD, the reaction toward the Kunitz soybean trypsin inhibitor (STI) attracted our attention (Takahara et al. 1985). The effect of the enzyme on STI activity was remarkable as treatment with this PAD rapidly abolished the inhibitory activity of STI without altering its overall conformation; complete inactivation of STI was attained within several minutes at 37 °C. Surprisingly, only the modified arginine residue was the reactive site (or primary contact site) despite the fact that all of the remaining nine arginine residues in STI are exposed on the protein surface (Takahara et al. 1985). This study was first an indication of a biological function for the deimination and biochemical application of PAD. Furthermore, the observation that skeletal muscle PAD showed a high affinity for only the functional arginine residue in STI inspired the idea of an effective affinity adsorbent composed of immobilized STI for PAD purification. Our expectation was fully realized, as a 1800-fold purification with 50% yield was achieved by this affinity column (Takahara et al. 1986). Thereafter, we could supply a sufficient amount of purified rabbit skeletal muscle PAD to other researchers. Although recombinant enzymes from various sources superseded the rabbit skeletal muscle PAD since the latter half of the 1990s, the natural enzyme is still under requisition today. Several earlier experiments conducted with rabbit skeletal muscle PAD elicited important insights into the physiology and pathophysiology of protein deimination. For instance, our collaborative work with Dr. Masaki Inagaki (Aichi Cancer Center, Japan) provided very interesting results. In general, vimentin, an intermediate filament protein, is expressed by various cells and forms a stable, less dynamic molecular network. In 1989, we found that there was a complete loss of filament-forming ability of vimentin after PAD treatment. The enzyme could also deiminate the filaments that had been polymerized and induced filament disassembly. The deimination reduced the isoelectric point of the head domain, in which the positive charge of arginine residues are essential for maintaining the ability to form filaments, resulting in the complete loss of their intermediate filament constructs. Similar results were obtained with other intermediate filaments such as desmin and glial fibrillary acidic protein (GFAP) (Inagaki et al. 1989). Thus, we presumed that deimination of intermediated filaments controls the cytoskeletal network. This hypothesis was verified by several subsequent reports by others in the field. In particular, deiminated vimentin was found *in vivo*, and this modification triggers structural collapse and promotes apoptosis (Asaga et al. 1998; Hsu et al. 2014). There is also some evidence that deimination of GFAP is a characteristic feature of neurodegenerative diseases (Ishigami et al. 2005).

In parallel with research on rabbit skeletal muscle PAD, we attempted to develop a model system using the mouse/rat for investigation of the physiological function of PAD. From 1988, Dr. Tatsuo Senshu (Tokyo Metropolitan Institute of Gerontology, Japan) started his investigations into the PADs. Together, by 1995, our findings, coupled with those of Senshu's laboratory, established that PAD is widely distributed in many tissues with the notable exception of serum and the location of the enzyme was essentially in cytoplasm. Among the tissues tested thus far, the activity of PAD in the salivary glands, pancreas, and uterus far exceeded those of any other tissues.

Immunohistochemical analyses indicated that the enzyme is preferentially located in acinar cells of the salivary glands and pancreas and in the luminal and glandular epithelia of the uterus (Takahara et al. 1989; Watanabe et al. 1988). Additionally, we noted estrous cycle-dependent changes in enzyme expression in the uterus, with the level being highest and lowest at diestrus (Takahara et al. 1989). Senshu's group also found estrous cycle-dependent change of this enzyme in the rat pituitary gland (Senshu et al. 1989). The expression of PAD in the pituitary and uterus responds adequately to administration with 17β -estradiol (Senshu et al. 1989; Takahara et al. 1992). In the uterus, a remarkable series of events takes place during the estrous cycle. The luminal and glandular epithelia of the uterus at the estrous stage show hyperplasia and vigorously secrete fluid into the lumen. Therefore, PAD may be important for exocrine events, but the physiological roles of PAD in the uterus and pituitary are still unknown.

During investigations of PAD activity in the skin, we had a question: why are the substrate specificities of the skeletal muscle PAD toward several arginine derivatives different from those of the epidermal PAD reported previously (Fujisaki and Sugawara 1981)? Both PADs showed high activity toward the synthetic arginine derivatives blocked at the N- and C-termini (i.e., benzoyl-L-arginine ethyl ester), whereas the skeletal muscle PAD showed very low activity to C-terminal free arginine derivatives such as benzoyl-L-arginine and acetyl-L-arginine. On the other hand, these C-terminal free substrates were comparably processed by epidermal PAD. This question was resolved by our comprehensive work published in 1991 (Terakawa et al. 1991). We compared the elution profiles of the PAD activities of the extracts from several tissues of mouse using anion-exchange chromatography, in which PAD activity was simultaneously measured with the different substrates. As shown in Fig. 1.2, three peaks were eluted upon chromatography of the skin extract. Since each peak showed different substrate specificities, we proposed designating them as peptidylarginine deiminase type I (PAD1), II (PAD2), and III (PAD3) according to the order of elution. The extracts of the skeletal muscle, pancreas, salivary gland, and brain (spinal cord) showed a single peak that corresponded to type II enzyme. Type I enzyme is specifically located in the uterus and epidermal cells, and type III enzyme is present in the hair follicle. These three types of enzyme were not significantly different in catalytic properties, including absolute dependence on calcium ions for activity and the stimulation with DTT. Senshu's group also described the presence of three isozymes in rat tissues and called them "epidermal type, skeletal muscle type, and hair follicle type," which correspond to PAD1, PAD2, and PAD3, respectively (Watanabe et al. 1988). Thereafter, by innovative techniques such as molecular genetics and proteomics, two new PAD isozymes were found in rat epidermis (Yamakoshi et al. 1998)/a keratinocyte cell line (Ishigami et al. 1998) and in the mouse ovary (Wright et al. 2003), and they were named PAD4 and ePAD, respectively. In 1999, Dr. Michiyuki Yamada (Yokohama City University, Japan) and colleagues identified a novel PAD in human myeloid leukemia HL-60 cells, which can induce to differentiate into granulocytes by retinoic acid (Nakashima et al. 1999). By comparison of the amino acid sequence and substrate specificity of HL-60 PAD with those of the four known rat PADs, they




Fig. 1.2 DEAE-Sephacel ion-exchange column chromatography of the PAD activity from various tissues from mouse. The substrates used for measuring PAD activity were Benzoyl-L-Arg-O-ethyl ester (*open circle*), Benzoyl-L-Arg (*open triangle*), and protamine (*filled circle*)

concluded that HL-60 PAD did not belong to any PADs and named it PAD5 (Nakashima et al. 1999). However, human PAD5 proved to be the human orthologue of mouse PAD4 (Chavanas et al. 2004), and it was subsequently named PAD4 by the HUGO Gene Nomenclature committee (HGNC). In addition, to avoid confusion, the HGNC recommended that PAD5 remains unused and ePAD be renamed PAD6. In total, it is now recognized that there are five PAD isozymes, i.e., PAD1, PAD2, PAD3, PAD4, and PAD6.

Cloning of the cDNAs for the five PAD isozymes was a historic struggle that stretched from 1989 to 2004. In 1989, Watanabe and Senshu first reported on the cDNA of rat PAD2 and deduced its amino acid sequence (Watanabe and Senshu 1989). Four years later, we revealed at long last in the full nucleotide sequence of mouse the PAD2 cDNA (Tsuchida et al. 1993). Looking back on that time, we had to overcome several obstacles to reach our goal. The N-terminal amino acid sequence of mouse PAD2 was N^α-acetyl-Met-Gln-, a sequence which has never previously been reported among N^α-acetyl-Met protein. As such, it was difficult to assign the methionine codon (ATG) at the translational start of the cDNA. In 1997, we purified a small amount of PAD3 from newborn rat epidermis by a procedure that included STI-affinity chromatography and carried out peptide mapping by the in situ protease digestion method (Nishijyo et al. 1997). Subsequently, we succeeded in cloning the cDNA and sequenced the full-length cDNA encoding rat PAD3 by RT-PCR and 3′-5′-RACE methods using synthesized nucleotide primers designed from the internal amino acid sequences (Nishijyo et al. 1997). This was the first report exhibiting the entire amino acid sequence of the isozyme, and by alignment of the PAD2 and PAD3 sequences, we found that a half of C-terminal region was highly conserved, and we predicted that the conserved region was likely responsible for the catalytic activity of this enzyme. This notion was ultimately proved by the excellent works of Dr. Mamoru Sato (Yokohama City University, Japan) and his coworkers in 2004, who determined the X-ray crystal structure of human PAD4 (Arita et al. 2004). These leading researches ultimately resulted in the cloning of the cDNAs for other PAD isozymes. Most cDNA isozymes from the rodent (Yamakoshi et al. 1998; Ishigami et al. 1998; Wright et al. 2003; Watanabe and Senshu 1989; Tsuchida et al. 1993; Nishijyo et al. 1997; Rus'd et al. 1999) and human PAD (Nakashima et al. 1999; Chavanas et al. 2004; Kanno et al. 2000; Ishigami et al. 2002; Guerrin et al. 2003) were established in laboratories in Japan. In addition, we produced the bacterial recombinant PADs of mouse and human in run-up to other laboratories (Ohsugi et al. 1995). The constructed plasmids had a unique DNA linker containing a pair of Shine-Dalgarno sequences and a short preceding cistron inserted into the adjacent 5′-region of the coding region, so that we could obtain a large quantity of the PADs without a sequence tag in bacteria. These recombinant PADs were also easily purified by STI-affinity chromatography and helped a great deal for many investigations (Ohsugi et al. 1995).

In 1992, Senshu and coworkers developed an excellent procedure for the detection of deiminated proteins on membranes or fixed tissues (Senshu et al. 1992). This method involves a three-step process. In the first step, citrulline-containing proteins immobilized on the membrane or fixed tissues are chemically modified. In the